MBody AI Ltd. Ordinary Share (MBAI) Stock Price

MBAIStock
$2.75−81.20%52W
Market Cap$42.06M
P/E10.16x
PEG Ratio—
Div yield—
Beta0.77

MBAI Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-87.58%
Price vs S&P 500 (4W)-54.39%
VGM Score10.43
P/E Ratio (Annual)10.16x

MBAI Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q3 2023-$0.17-$0.43-154.24%(-$0.26)
Q2 2023-$0.53-$0.94-77.89%(-$0.41)
Q1 2023-$0.74-$0.76-2.70%(-$0.02)
Q4 2022-$0.98-$0.64+35.20%(+$0.35)

MBAI Analyst Recommendations

Apr 2024
May 2024
Jun 2024
Jul 2024
2.17
2.17
2.17
2.17

Industry Peers — X-Ray Equipment(5)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth (5Y)Gross Margin (TTM)Operating Margin (TTM)Price
MBAIMBody AI Ltd. Ordinary Share
——F————$2.75
GEHCGE HealthCare Technologies Inc. Common StockBDB1.5x3.7%39.5%12.9%$69.57
PHGKONINKLIJKE PHILIPS N.V.BDB1.3x0.6%45.9%9.7%$25.74
BFLYButterfly Network, Inc.FAB17.5x—52.6%-70.8%$7.25
NNOXNANO-X IMAGING LTD Ordinary SharesAAF2.3x—-77.2%-765.6%$0.45
HOLXHologic IncCDB4.1x1.7%56.5%17.6%$0.00

About MBody AI Ltd. Ordinary Share

Check-Cap Ltd is a clinical-stage diagnostics company developing C-Scan, an ingestible capsule that uses low-dose X-rays to screen for colorectal cancer and polyps without patient preparation or data retrieval. The swallowed capsule naturally transits the gastrointestinal tract while imaging, eliminating the need for colonoscopy prep. Based in Israel, the company plans to commercialize the technology in the United States, Europe, and Japan.